Message boards index | Help | Search messages | Sign in


+ UKCAB + Public area + News, events, announcments + NICE work programme referrals - May 2011

NICE work programme referrals - May 2011

Print
Pages: 1

kevinkelleher
Guest
NICE work programme referrals - May 2011
Posted on: May 18 2011, 04:24 pm

Single Technology Appraisals

 

    To appraise the clinical and cost effectiveness of vernakalant within its licensed indication for the treatment of rapid conversion of recent onset atrial fibrillation ≤ 7 days.
    To appraise the clinical and cost effectiveness of canakinumab within its licensed indication for the treatment of gouty arthritis attacks.
    To appraise the clinical and cost effectiveness of boceprevir within its licensed indication for the treatment of genotype 1 chronic hepatitis C.
    To appraise the clinical and cost effectiveness of telaprevir within its licensed indication for the treatment of genotype 1 chronic hepatitis C.
    To appraise the clinical and cost effectiveness of abiraterone in combination with prednisolone within its licensed indication for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy.
    To appraise the clinical and cost effectiveness of rivaroxaban within its licensed indication for the prevention of venous thromboembolism in people hospitalised for acute medical conditions.

http://www.dh.gov.uk/en/Healthcare/Medicinespharmacyandindustry/Prescriptions/TopicsreferredtoNICE/DH_126926
Logged

Print
Pages: 1

+ UKCAB + Public area + News, events, announcments + NICE work programme referrals - May 2011